2026 H1 -tulosraportti
UUTTA
4 päivää sitten
‧45 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sitten · MuokattuThis came on TekInvestor yesterday (Artic) Thor Medical ASA Recommendation: Buy · Target Price: NOK 8.7 (5.0) · Current Share Price: NOK 5.68 Self-scaling production and hidden isotope demand support material upside We reiterate our Buy recommendation and raise our target price to NOK 8.7 per share, from NOK 5.0 previously, reflecting updated modelling assumptions and a revised valuation methodology following the change of lead analyst. We believe the current share price materially underestimates Thor Medical’s long-term potential. In particular, we think the market underappreciates isotope demand created by losses across the radiopharma value chain. We also believe the self-scaling economics of Thor Medical’s production process, as reusable Th-232 feedstock accumulates over time, are not fully reflected in the share price. Our new bottom-up analysis explicitly models both effects, providing a more granular view of the company’s long-term revenue and margin potential
Thor has a large upside, and some of that upside I believe is already priced into the share price. I believe the share price will remain around 5 for some time going forward. If there are plans for scaling up with more production units, it can rise immediately, but I don't believe that will happen until there is a medicine that is approved and proven effective where Thor's product is used. Alternatively, it must be shown that Thor is operating at a profit. If such a medicine comes, I believe the USA will be the next unit for production. And then it is possible that Thor will also be sold. I am waiting for +/- 5 before I buy more.
·12 t sittenI often sit and look at the top 100 investors and if there are any movements. I find it a bit interesting to see what is actually happening on the ownership side. Yes, I know there's a 1-2 day delay on the shareholder register, but so far there are virtually no changes. There has been a quite strong increase in the share price recently, followed by a correction after the report. That's actually not so surprising. After such a price increase, there will always be some who take profit, and short-term traders who go in and out. What one can notice is that the shareholders/top 50 have not moved much at all. At least not so far. For me, that's quite a positive signal. If those holding the largest positions truly believed that the case was overpriced after the increase, one might perhaps have expected some of them to start reducing their holdings. So far, that doesn't seem to be the case. Of course, that doesn't mean the price will go straight back up. The share can easily fall further in the short term, especially after the strong increase we've had. But there's a difference between the share correcting because someone takes profit/sells due to stop-loss or fear, and the largest long-term owners starting to abandon the case; here it definitely seems that the former is the case. I therefore think it's a bit too early to interpret the price drop as the market having lost faith in Thor or that a share issue is right around the corner. Many of the calculations in here are completely outrageous. For some, it can apparently seem like they are building a factory per quarter considering the costs they believe they have every month going forward. For my part, it's still the future development, customer agreements and the path forward towards AlphaTwo/AlphaGlobal that is interesting. The price naturally moves from day to day. The large owners are sitting completely still. At least that's how it looks so far. I think that's worth noting. Especially for those who believe they have placed buy orders at both 4 and 3 kroner 😂🔥
RobertBorgaas, well I can mention that Olili has sold 23 million shares. At least it's clear to see that he felt the case was overpriced. And there are several others who have also sold out.
·15 t sittenBuying more in the 4s
·17 t sittenAdvanCell brings Pb-212 to Melbourne this week. At ProsTIC26 on September 3–5, they are presenting TheraPb phase 1b with 212Pb-ADVC001 against prostate cancer. One about how the agent works. Two about the practical aspects: how much radiation the staff receives, and when the patient can go home. The latter is important. Pb-212 lives for 10.6 hours. This makes discharge and radiation protection easier than with isotopes that remain for days. When a company dares to show such data at a prostate congress, they are beyond "this only exists in the lab". Thor Medical is a partner and supplier of Th-228 to AdvanCell. The further TheraPb progresses, the more raw material is needed. https://www.linkedin.com/posts/prostic26-prostic26-212pb-share-7499837907306790912-0gmj/?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
10 t sittenAdvanCell’s participation in the ProsTIC26 symposium in Melbourne (September 3–5) signals that its Pb-212-PSMA therapy (ADVC001 / TheraPb) is transitioning from early-stage data toward clinical validation at leading theranostics centers. ProsTIC is one of the world’s premier PSMA-RLT centers, accepting only those programs that demonstrate a truly promising clinical signal and a robust supply chain.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 H1 -tulosraportti
UUTTA
4 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuThis came on TekInvestor yesterday (Artic) Thor Medical ASA Recommendation: Buy · Target Price: NOK 8.7 (5.0) · Current Share Price: NOK 5.68 Self-scaling production and hidden isotope demand support material upside We reiterate our Buy recommendation and raise our target price to NOK 8.7 per share, from NOK 5.0 previously, reflecting updated modelling assumptions and a revised valuation methodology following the change of lead analyst. We believe the current share price materially underestimates Thor Medical’s long-term potential. In particular, we think the market underappreciates isotope demand created by losses across the radiopharma value chain. We also believe the self-scaling economics of Thor Medical’s production process, as reusable Th-232 feedstock accumulates over time, are not fully reflected in the share price. Our new bottom-up analysis explicitly models both effects, providing a more granular view of the company’s long-term revenue and margin potentialThor has a large upside, and some of that upside I believe is already priced into the share price. I believe the share price will remain around 5 for some time going forward. If there are plans for scaling up with more production units, it can rise immediately, but I don't believe that will happen until there is a medicine that is approved and proven effective where Thor's product is used. Alternatively, it must be shown that Thor is operating at a profit. If such a medicine comes, I believe the USA will be the next unit for production. And then it is possible that Thor will also be sold. I am waiting for +/- 5 before I buy more.
- ·12 t sittenI often sit and look at the top 100 investors and if there are any movements. I find it a bit interesting to see what is actually happening on the ownership side. Yes, I know there's a 1-2 day delay on the shareholder register, but so far there are virtually no changes. There has been a quite strong increase in the share price recently, followed by a correction after the report. That's actually not so surprising. After such a price increase, there will always be some who take profit, and short-term traders who go in and out. What one can notice is that the shareholders/top 50 have not moved much at all. At least not so far. For me, that's quite a positive signal. If those holding the largest positions truly believed that the case was overpriced after the increase, one might perhaps have expected some of them to start reducing their holdings. So far, that doesn't seem to be the case. Of course, that doesn't mean the price will go straight back up. The share can easily fall further in the short term, especially after the strong increase we've had. But there's a difference between the share correcting because someone takes profit/sells due to stop-loss or fear, and the largest long-term owners starting to abandon the case; here it definitely seems that the former is the case. I therefore think it's a bit too early to interpret the price drop as the market having lost faith in Thor or that a share issue is right around the corner. Many of the calculations in here are completely outrageous. For some, it can apparently seem like they are building a factory per quarter considering the costs they believe they have every month going forward. For my part, it's still the future development, customer agreements and the path forward towards AlphaTwo/AlphaGlobal that is interesting. The price naturally moves from day to day. The large owners are sitting completely still. At least that's how it looks so far. I think that's worth noting. Especially for those who believe they have placed buy orders at both 4 and 3 kroner 😂🔥RobertBorgaas, well I can mention that Olili has sold 23 million shares. At least it's clear to see that he felt the case was overpriced. And there are several others who have also sold out.
- ·15 t sittenBuying more in the 4s
- ·17 t sittenAdvanCell brings Pb-212 to Melbourne this week. At ProsTIC26 on September 3–5, they are presenting TheraPb phase 1b with 212Pb-ADVC001 against prostate cancer. One about how the agent works. Two about the practical aspects: how much radiation the staff receives, and when the patient can go home. The latter is important. Pb-212 lives for 10.6 hours. This makes discharge and radiation protection easier than with isotopes that remain for days. When a company dares to show such data at a prostate congress, they are beyond "this only exists in the lab". Thor Medical is a partner and supplier of Th-228 to AdvanCell. The further TheraPb progresses, the more raw material is needed. https://www.linkedin.com/posts/prostic26-prostic26-212pb-share-7499837907306790912-0gmj/?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY10 t sittenAdvanCell’s participation in the ProsTIC26 symposium in Melbourne (September 3–5) signals that its Pb-212-PSMA therapy (ADVC001 / TheraPb) is transitioning from early-stage data toward clinical validation at leading theranostics centers. ProsTIC is one of the world’s premier PSMA-RLT centers, accepting only those programs that demonstrate a truly promising clinical signal and a robust supply chain.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
2026 H1 -tulosraportti
UUTTA
4 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuThis came on TekInvestor yesterday (Artic) Thor Medical ASA Recommendation: Buy · Target Price: NOK 8.7 (5.0) · Current Share Price: NOK 5.68 Self-scaling production and hidden isotope demand support material upside We reiterate our Buy recommendation and raise our target price to NOK 8.7 per share, from NOK 5.0 previously, reflecting updated modelling assumptions and a revised valuation methodology following the change of lead analyst. We believe the current share price materially underestimates Thor Medical’s long-term potential. In particular, we think the market underappreciates isotope demand created by losses across the radiopharma value chain. We also believe the self-scaling economics of Thor Medical’s production process, as reusable Th-232 feedstock accumulates over time, are not fully reflected in the share price. Our new bottom-up analysis explicitly models both effects, providing a more granular view of the company’s long-term revenue and margin potentialThor has a large upside, and some of that upside I believe is already priced into the share price. I believe the share price will remain around 5 for some time going forward. If there are plans for scaling up with more production units, it can rise immediately, but I don't believe that will happen until there is a medicine that is approved and proven effective where Thor's product is used. Alternatively, it must be shown that Thor is operating at a profit. If such a medicine comes, I believe the USA will be the next unit for production. And then it is possible that Thor will also be sold. I am waiting for +/- 5 before I buy more.
- ·12 t sittenI often sit and look at the top 100 investors and if there are any movements. I find it a bit interesting to see what is actually happening on the ownership side. Yes, I know there's a 1-2 day delay on the shareholder register, but so far there are virtually no changes. There has been a quite strong increase in the share price recently, followed by a correction after the report. That's actually not so surprising. After such a price increase, there will always be some who take profit, and short-term traders who go in and out. What one can notice is that the shareholders/top 50 have not moved much at all. At least not so far. For me, that's quite a positive signal. If those holding the largest positions truly believed that the case was overpriced after the increase, one might perhaps have expected some of them to start reducing their holdings. So far, that doesn't seem to be the case. Of course, that doesn't mean the price will go straight back up. The share can easily fall further in the short term, especially after the strong increase we've had. But there's a difference between the share correcting because someone takes profit/sells due to stop-loss or fear, and the largest long-term owners starting to abandon the case; here it definitely seems that the former is the case. I therefore think it's a bit too early to interpret the price drop as the market having lost faith in Thor or that a share issue is right around the corner. Many of the calculations in here are completely outrageous. For some, it can apparently seem like they are building a factory per quarter considering the costs they believe they have every month going forward. For my part, it's still the future development, customer agreements and the path forward towards AlphaTwo/AlphaGlobal that is interesting. The price naturally moves from day to day. The large owners are sitting completely still. At least that's how it looks so far. I think that's worth noting. Especially for those who believe they have placed buy orders at both 4 and 3 kroner 😂🔥RobertBorgaas, well I can mention that Olili has sold 23 million shares. At least it's clear to see that he felt the case was overpriced. And there are several others who have also sold out.
- ·15 t sittenBuying more in the 4s
- ·17 t sittenAdvanCell brings Pb-212 to Melbourne this week. At ProsTIC26 on September 3–5, they are presenting TheraPb phase 1b with 212Pb-ADVC001 against prostate cancer. One about how the agent works. Two about the practical aspects: how much radiation the staff receives, and when the patient can go home. The latter is important. Pb-212 lives for 10.6 hours. This makes discharge and radiation protection easier than with isotopes that remain for days. When a company dares to show such data at a prostate congress, they are beyond "this only exists in the lab". Thor Medical is a partner and supplier of Th-228 to AdvanCell. The further TheraPb progresses, the more raw material is needed. https://www.linkedin.com/posts/prostic26-prostic26-212pb-share-7499837907306790912-0gmj/?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY10 t sittenAdvanCell’s participation in the ProsTIC26 symposium in Melbourne (September 3–5) signals that its Pb-212-PSMA therapy (ADVC001 / TheraPb) is transitioning from early-stage data toward clinical validation at leading theranostics centers. ProsTIC is one of the world’s premier PSMA-RLT centers, accepting only those programs that demonstrate a truly promising clinical signal and a robust supply chain.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt